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Abstract
Background: Overexpression of the RON receptor tyrosine kinase contributes to epithelial cell transformation,
malignant progression, and acquired drug resistance. RON also has been considered as a potential target for
therapeutic intervention. This study determines biochemical features and inhibitory activity of a mouse monoclonal
antibody (mAb) Zt/f2 in experimental cancer therapy.
Results: Zt/f2 is a mouse IgG2a mAb that is highly specific and sensitive to human RON and its oncogenic variants
such as RON160 (ED50 = 2.3 nmol/L). Receptor binding studies revealed that Zt/f2 interacts with an epitope(s)
located in a 49 amino acid sequence coded by exon 11 in the RON b-chain extracellular sequences. This sequence
is critical in regulating RON maturation and phosphorylation. Zt/f2 did not compete with ligand macrophage-
stimulating protein for binding to RON; however, its engagement effectively induced RON internalization, which
diminishes RON expression and impairs downstream signaling activation. These biochemical features provide the
cellular basis for the use of Zt/f2 to inhibit tumor growth in animal model. Repeated administration of Zt/f2 as a
single agent into Balb/c mice results in partial inhibition of tumor growth caused by transformed NIH-3T3 cells
expressing oncogenic RON160. Colon cancer HT-29 cell-mediated tumor growth in athymic nude mice also was
attenuated following Zt/f2 treatment. In both cases, ~50% inhibition of tumor growth as measured by tumor
volume was achieved. Moreover, Zt/f2 in combination with 5-fluorouracil showed an enhanced inhibition effect of
~80% on HT-29 cell-mediated tumor growth in vivo.
Conclusions: Zt/f2 is a potential therapeutic mAb capable of inhibiting RON-mediated oncogenesis by colon
cancer cells in animal models. The inhibitory effect of Zt/f2 in vivo in combination with chemoagent 5-fluorouracil
could represent a novel strategy for future colon cancer therapy.
Background
The RON (recepteur d’origine nantais) protein belongs to
the MET proto-oncogene family [1], which constitutes a
unique subfamily of receptor tyrosine kinases [2]. Roles
of RON in tumor progression have been studied in both
in vitro and in vivo models [3]. RON is overexpressed in
various types of primary tumor samples including colon,
breast, and pancreatic cancers [4-7]. In colon and breast
cancers, RON overexpression associates with the diseases
at any stage and serve as an independent predictor of
subsequent relapse [6-8]. Transgenic studies show that
RON overexpression in lung and mammalian tissue
causes tumor formation and promotes tumor metastasis
[9-11]. Biochemically, RON overexpression results in
constitutive tyrosine phosphorylation, which stimulates
downstream signaling cascades including RAS-MAP
kinase and PI-3 kinase-AKT pathways [3,12]. These
activities lead to cell morphological changes with
increased cell invasive activity [13,14]. Clearly, altered
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malignant phenotypes of epithelial cancers.
RON is a 180 kDa heterodimeric protein composed of
a 40 kDa extracellular a-chain and a 150 kDa transmem-
brane b-chain with intrinsic tyrosine kinase activity [1].
RON is recognized and activated by a ligand known as
macrophage-stimulating protein (MSP) [15,16], also
known as hepatocyte growth factor-like protein [17]. The
binding of MSP to RON extracellular sequences causes
receptor dimerization, which leads to auto-phosphoryla-
tion of tyrosine residues in the intracellular sequences,
creates the docking motifs for interaction with signaling
molecules, and subsequently increases the tyrosine kinase
activity [18]. The RON extracellular sequences contain
several functional motifs including a sema domain fol-
lowed by a cysteine-rich hinge (PSI), three immunoglo-
bulin-plexin-transcription (IPT) units, and a peptide of
97 amino acids previously thought to contain the 4
th IPT
unit [1]. The sema domain stretches in both a and b
chains and is known to contain high affinity binding site
for MSP [19,20]. The exact role of PSI is unknown. PSI
seems to act as a link that regulates receptor conforma-
tion upon MSP binding to RON [18]. The IPT units are
important in RON activity. Elimination of the first IPT
domain coded by exons 5 and 6 results in the formation
of a RON variant known as RON160, which possesses
oncogenic activity [21]. Functions of the second and
third IPT units are currently unknown. A 97 amino acid
peptide (from Pro
861 to Thr
957) stretches between the
last amino acid Leu
860 of the 3
rd IPT and the first amino
acid Leu
958 of the transmembrane segment [22]. Forty-
nine amino acids (from Tyr
884 to Gln
930) in this sequence
are coded by exon 11, which often is deleted through the
splicing process [23,24]. This deletion results in forma-
tion of a single-chain precursor RON165, which is
retained in cytoplasm [23,24]. Exon 11 deletion also
causes spontaneous RON dimerization and phosphoryla-
tion [23,24]. Thus, the sequences encoded by Exon 11
are critical in RON maturation and activation process
(referred as maturation-required sequences, MRS). Con-
sidering the importance of extracellular domains in
ligand binding, receptor maturation, and activation, it is
believed that biological or chemical agents that specifi-
cally interact with these domains should regulate RON
activation and control its downstream signaling events.
Such studies should also provide a basis for the develop-
ment of potential therapeutics designed to inhibit RON-
mediated tumorigenesis.
Pathogenesis of RON in epithelial cancer has made this
receptor an attractive drug target [25-27]. Potential ther-
apeutics including small molecule kinase inhibitors
(SMI), mAbs and small interfering (si) RNA have been
developed and tested to block RON-mediated tumorigen-
esis [14,25-28]. Results from these studies demonstrate
that blocking RON signals contributes to reduced cell
growth, diminished cell invasiveness, and impaired tumor
metastasis. Studies from in vivo models further demon-
strate that SMI and mAb specific to RON inhibit tumor
growth in various xenograft models [25,26]. Thus, RON
is a drug-targeting candidate, which has potential to be
used clinically in targeted cancer therapy. The present
work determines the biological features of a novel mAb
specific to MRS in RON extracellular sequences. Bio-
chemical analysis indicates that the interaction of the
mAb with MRS facilitates RON internalization followed
by degradation. Moreover, administration of this mAb
a sas i n g l ea g e n tp a r t i a l l yi n h i b i t sx e n o g r a f tt u m o r
growth in vivo and potentiates the cytotoxic effects of
chemotherapeutics.
Results
Biochemical characterization of mAb Zt/f2 specific to
human RON
Anti-RON mAbs were obtained by classical hybridoma
methods [4,29] and characterized (Table 1). Zt/f2 was
selected for further evaluation. Immunofluorescent analy-
sis indicated that Zt/f2 binds to an epitope(s) on RON
extracellular sequences (Figure 1A) and displays similar
binding affinity as Zt/g4 at a defined concentration. Zt/f2
recognized the native RON receptor but not denatured
protein under reduced conditions (data not shown). Spe-
cies cross-reactivity studies showed that Zt/f2 is highly
specific to human RON and does not recognize RON
homologues expressed by monkey, dog, rat, and mouse
(Figure 1B). Immunoprecipitation analysis of the cross-
reactivity with different RTK proteins showed that Zt/f2
at 10 μg per ml fails to recognize MET, EGFR, IGFR,
FGFR, and VEGFR (Figure 1C). To determine if Zt/f2
competes with MSP or Zt/g4 for binding to RON, we
performed binding competition experiments. Results in
Figure 1D showed that the binding of 3 nM FITC-labeled
Zt/f2 to 3T3-RON cells was not inhibited by increased
amounts of MSP. The fluorescence intensity from indivi-
dual samples containing MSP ranging from 1 to 40 nM
was all overlaid with the sample containing Zt/f2 alone.
Similarly, the Zt/f2 binding to RON was not replaced by
the increased amounts of Zt/g4 (Figure 1E), which recog-
nizes RON sema domain [29]. Taken together, results in
Figure 1 demonstrate that mAb Zt/f2 is highly specific
and sensitive to human RON. It binds to an epitope(s) on
the RON extracellular sequences, which differs from
MSP and Zt/g4.
Recognition by Zt/f2 of MRS in the RON extracellular
domains
To determine the potential binding region of Zt/f2, we
first tested if Zt/f2 binds to a naturally occurring RON
v a r i a n t( k n o w na sR O N s e m a )c o m p r i s i n gt h ee n t i r e
Yao et al. Molecular Cancer 2011, 10:82
http://www.molecular-cancer.com/content/10/1/82
Page 2 of 12sema domain, PSI hinge, and a N-terminal portion of
the first IPT unit [20]. Results from co-immunoprecipi-
tation showed that control mAb Zt/g4 and Zt/#1
strongly interacted with the RONsema (Figure 2A), indi-
cating that these mAbs bind to an epitope(s) located on
the RONsema proteins. However, incubation of Zt/f2
with RONsema did not result in any detectable RON-
sema in Western blot analysis after co-immunoprecipi-
tation (Figure 2A), suggesting that the binding region of
Zt/f2 is not located on the RONsema protein.
The interaction of Zt/f2 with RON160, RON165,
RON155, and RON110 was then tested with lysates from
NIH-3T3 cells expressing individual RON variants [30].
These variants have deletion in the first IPT unit
(RON160), MRS (RON165), the first IPT plus MRS
(RON155), and truncation at the first IPT unit (RON110)
(Figure 2B) [30]. Results in Figure 2C showed that Zt/f2
recognizes RON, RON160, and RON110, all of which con-
tain MRS. However, Zt/f2 did not recognize RON155 and
RON165, since both lack MRS. Immunofluorescence ana-
lysis of Zt/f2 binding to 3T3 cells expressing individual
RON variants confirmed these results (Figure 2D). Zt/f2
binds to RON and RON160 with comparable affinity. The
affinity of Zt/f2 binding to RON110 was moderate. How-
ever, Zt/f2 failed to bind to RON165 or RON155. To con-
firm if MRS was involved, Zt/f2 was pre-incubated with a
49 amino acid peptide coded by exon 11 followed by fluor-
escence cell surface analysis. Results in Figure 2E show
that after pre-incubation, Zt/f2 almost completely lost the
ability to bind to RON. Similar results were also seen in
3T3-RON160 cells (data not shown). Taken together,
results in Figure 2 demonstrate that Zt/f2 recognizes an
epitope(s) located in MRS coded by exon 11 in the RON
b-chain extracellular sequences.
Effect of Zt/f2 on RON phosphorylation and downstream
signaling cascades
Deletion of MRS results in constitutive phosphorylation of
RON [23,24]. To determine if Zt/f2 binding to this region
affects RON activation, cells were serum-starved overnight
and treated with MSP or Zt/f2 for 15 min. A trace of RON
and RON160 phosphorylation was detected in HT-29 cells
(Figure 3A). MSP stimulation slightly increased the levels
of phosphorylation. Zt/f2 treatment alone results in a
slight increase in RON phosphorylation. A moderate level
of synergism in RON phosphorylation was observed when
Zt/f2 was combined with MSP. Also, Zt/f2 alone moder-
ately increased Erk1/2 and AKT phosphorylation. We
observed a moderate increase in Erk1/2 or AKT phos-
phorylation when MSP and Zt/f2 were combined. To
study if phosphorylation translates into cell proliferation,
the effect of Zt/f2 on HT-29 cell growth was determined.
Treatment of cells with Zt/f2 for three days moderately
inhibited cell growth compared to control or MSP-stimu-
lated cells (Figure 3B). Similarly, Zt/f2 moderately inhib-
ited MSP-induced cell proliferation. Analysis of cell
transmembrane migration revealed that Zt/f2 only has
marginal effect on HT-29 cell migration (Figure 3C). A
moderate inhibition by Zt/f2 in MSP-induced cell migra-
tion also was observed. Taken together, results in Figure 3
suggest that although Zt/f2 slightly increases RON, Erk1/
2, and AKT phosphorylation, it moderately inhibits MSP-
stimulated or non-stimulated HT-29 cell growth but only
slightly prevents these cell migrations.
Table 1 Biochemical and Biological Features of Mouse Anti-RON Monoclonal Antibodies in Various Applications*
Features Zt/f2 Zt/#1 Zt/g9
IgG subtype IgG2a IgG1 IgG1
Specificity Only human RON Only human RON Only human RON
Recognition MRS Sema Sema
ED50 2.3 nmol/L 3.7 nmol/L 4.2 nmol/L
Reactivity to
Isoforms
RON++++ RON160++++
RON165
_
RON155
_
RON110+++
RON+++,
RON160++++,
RON165+++,
RON155++
RON110
_
RON+++,
RON160+++
RON165+++,
RON155++
RON110
_
Cross-reactivity with MET and EGFR Negative Negative Negative
Induction of phosphorylation +++ ++ ND
Western blotting Negative Negative Negative
Immunoprecipitation ++++ +++ ++++
Cell surface immunofluorescence ++++ +++ +++
Immunohistochemical staining ++++ ++ +++
Effect on RON expression Down-regulation Down-regulation ND
*The reactivity of Zt/f2, Zt/#1, and Zt/g9 in various immune assays were determined as detailed in Materials and Methods. For immunofluorescence and
immunoprecipitation, individual mAbs were used at 1 μg/ml per sample. In immunohistochemical staining, mAbs were used at 2 μg/ml. Experiments were
repeated twice. The reactivity/intensity indicated by + or-was obtained by comparing to anti-RON mAb Zt/g4 [29]. MRS, maturation-required sequences; ND, not
done.
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expression by various cancer cells
To determine how Zt/f2 inhibits HT-29 cell growth, we
studied the effect of Zt/f2 on RON/RON160 expression
by HT-29 cells. After cells were treated with Zt/f2 for
various time periods, levels of RON/RON160 expression
were determined by cell surface fluorescence analysis.
Results in Figure 4A showed that the binding of Zt/f2 to
HT-29 cells at 37°C caused the down-regulation of the
cell surface RON/RON160 expression. More than 80%
of cell surface fluorescence was reduced after Zt/f2 incu-
bation for 12 h. The down-regulation seemed to be
linked to cellular endocytosis because fluorescence
intensity was significantly recovered when endocytic
inhibitor filipin was used (Figure 4B) [31]. Filipin alone
had no effect on RON expression (data not shown);
however, when used with Zt/f2, Zt/f2-induced down-
regulation was significantly prevented. Western blot
Figure 1 Mouse mAb Zt/f2 is highly specific and sensitive to human RON: A) Zt/f2 recognizes an epitope on RON extracellular
sequences. 3T3-RON cells (0.5 × 10
6 cells per sample) were incubated at 4°C for 45 min with 1 μg/ml of Zt/f2, Zt/#1, Zt/g4, or control mouse
IgG, respectively. Goat anti-mouse IgG coupled with FITC were used as the detecting antibody followed by flow cytometry analysis. B) Zt/f2 does
not recognize RON homologues from different species. Cellular proteins (300 μg per sample) from cell lines known to express RON homologues
were incubated with Zt/f2 (10 μg per sample) overnight followed by addition of Protein G-Sepharose. Immunoprecipitated proteins were
separated in 8% SDS-PAGE under reduced conditions. Rabbit IgG cross-reacting with RON homologues (Santa Crutz Biotechnology) from
different species (50 μg cellular protein/sample from cell lines: human HCT116, monkey COS-1, canine MDCK, rat IEC18, and mouse peritoneal
macrophages) were used followed by ECL reactions. C) Zt/f2 only recognizes RON but not other RTKs. Cellular proteins (300 μg per sample) from
cell lines known to express MET (HCC1937), EGFR (BxPC3), VEGFR (HT-29), IGFR (AsPC-1), and FGFR (MDA-MB-361) were incubated with Zt/f2 (1
μg per sample) followed by immunoprecipitation with Protein G-Sepharose. Western blot analysis was performed as in B using specific
antibodies. D)& E) Zt/f2 does not compete with MSP or Zt/g4 for RON. 3T3-RON cells were incubated with 3 nM of FITC-labeled Zt/f2 alone or
with increased amounts of MSP (D) at 0, 5, 10, 20, 40, 60 nM, or Zt/g4 (E) at 0, 10, 25, 50, 100, and 160 nM, respectively. The fluorescent intensity
of each sample was plotted in individual figures.
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that Zt/f2 treatment results in a significant RON/
RON160 reduction (Figure 4C). Consistent with cell sur-
face fluorescence analysis, both RON and RON160
expression were progressively reduced up to 48 h after
Zt/f2 treatment. In control cells treated with normal
mouse IgG, the levels of RON expression were main-
tained. The diminished RON expression seems to be
caused by intracellular proteasomic degradation. Pre-
treatment of HT-29 cells with proteasomic inhibitor lac-
tacystin significantly prevented Zt/f2-induced RON/
RON160 reduction (Figure 4D). More than 90% of
Figure 2 Zt/f2 binds specifically to MRS in the RON b-chain extracellular sequence. A) Zt/f2 does not bind RONsema. Recombinant
RONsema (0.5 μg per sample) from transfected cells (Ma et al., 2010) was immunoprecipitated with 2 μg/ml Zt/f2 or other mAbs with Protein G-
Sepharose. Samples were analyzed under non-reduced conditions by Western blot analysis using antibodies to RON extracellular sequences
(Wang et al., 1994). B) Schematic representation of RON and its variants. General structures of RON are illustrated on the left. The a- and b-
chains are indicated. Deleted regions in individual variants are marked with arrows. TM, transmembrane segment; MRS, maturation-related
sequences; and TK, tyrosine kinase domain. C) Zt/f2 does not interact with RON165 and RON155. Cellular proteins (300 μg per sample) from
NIH3T3 cells expressing RON, RON160, RON165, RON155, or RON110 were immunoprecipitated with 2 μg/ml of Zt/f2. Samples were detected by
Western blot analysis using rabbit IgG antibody to RON C-terminal peptide (Xu et al., 2004). D) Zt/f2 does not bind to RON165 and RON155 in
intact cells. NIH3T3 cells expressing individual RON variants (0.5 × 10
6 cells per sample) were permeabilized as previously described (Lu et al.,
2007) and then incubated with 2 μg/ml of Zt/f2. Fluorescence was detected by FITC-coupled goat anti-mouse IgG. E) MRS peptide blocks Zt/f2
binding to RON. Zt/f2 (2 μg/ml) was first mixed with or without 1 μM of synthetic peptide for 30 min and then incubated with 3T3-RON cells.
Cell surface fluorescence was determined as described above.
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f2 plus 10 μg/ml of lactacystin. Thus, results in Figure 4
demonstrate that Zt/f2 treatment causes down-regula-
tion of RON/RON160 expression by HT-29 cells. The
reduced cell-surface RON/RON160 expression is
mediated by endocytosis and subsequent degradation
through proteasomic mechanism. The down-regulation
could lead to Zt/f2-induced reduction in cell growth
and migration seen in Figure 3.
Inhibitory effect of Zt/f2 in vivo on tumor growth
mediated by 3T3-RON160 or colon cancer cells
The effect of Zt/f2 on 3T3-RON160-mediated tumor
g r o w t hi ss h o w ni nF i g u r e5 .I nt h i sm o d e l ,Z t / f 2t r e a t -
ment was delayed three days after cell inoculation.
Tumor size increased in a time dependent manner
(growth index as 1.00 at day 32) in the control group.
An interesting finding was that Zt/g4 treatment slightly
increased tumor growth mediated by 3T3-RON160 cells.
In this case, a slight increase in tumor volume was
observed. In contrast, Zt/f2 administration resulted in
inhibition of tumor growth, an effect that was seen as
early as five days after Zt/f2 initial injection. An average
of 54% reduction in the tumor volume was observed as
compared to tumors from control mice.
The therapeutic effect of Zt/f2 also was validated on
colon HT-29 cell-mediated tumor model in athymic
nude mice. Experimental procedures were similar to
those described above. Repeated administration of Zt/f2
had an inhibitory effect on HT-29 tumor cell growth
Figure 3 Effect of Zt/f2 on RON/RON160 phosphorylation, cell proliferation, and migration by HT-29 cells. A) Serum-starved HT-29 cells
(3 × 10
6 cells/sample) were stimulated for 15 min at 37°C by 2 nM MSP, 10 μg/ml Zt/g4, or both followed by immunoprecipitation using Zt/g4.
Cells treated with control IgG served as the control. Phospho-RON/RON160 was determined by Western blot analysis using anti-PY100 mAb.
Phosphorylation of Erk1/2 and AKT were determined by Western blot analysis using specific antibodies. B) HT-29 cells in wells of a 96-well plate
(10,000 cells/well) were treated with MSP (2 nM), Zt/f2 (10 μg/ml), or both in triplicate for three days. Cells numbers were counted as detailed in
Materials and Methods. C) A 48-well cell migration chamber was used to determine levels of HT-29 cell migration in a period of 24 h. The
bottom wells of the chamber were filled with MSP (2 nM), Zt/f2 (10 μg/ml), or both. The top wells were filled with HT-29 cells (1 × 10
4 cells/
well) in DMEM with 5% FBS. Cells migrated and attached to the membrane were counted as previously described (Wang et al., 1994).
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Page 6 of 12(Figure 5B). An average of 56% reduction in tumor
volume was observed. Interestingly, Zt/g4 did not show
the significant agonistic effect on HT-29 cell-induced
tumor growth. These results, together with those from
Figure 5A, demonstrate that Zt/f2 treatment partially
inhibits tumor growth mediated not only by RON160
transformed mouse fibroblast cells, but also by colon
HT-29 cancer cells that naturally express RON and
RON160.
Effect of Ztf2 with 5-FU on tumor growth in nude mice
Results from above studies prompted us to study the
combination of Zt/f2 and 5-fluoracil (5-FU) in tumor
therapy. Tumor weight at the end of treatment was
used as the evaluation marker. Results in Figure 6A
show the inhibitory effect of Zt/f2, 5-FU, and combined
treatment on HT-29 tumor growth in athymic nude
mice. Treatment with 5-FU alone showed 59% decrease
in tumor growth when compared with saline-treated
mice. Administration of Zt/f2 as a single agent also
caused 51% decrease in tumor weight. However, the
combined treatment (Zt/f2 and 5-FU) showed maximal
inhibition with a decrease of 80% in tumor weight.
Furthermore, comparative survival rate results among
different groups confirmed the effectiveness of the com-
bined treatment (Figure 6B). All eight mice in the saline
group died within 30 days due to complication of tumor
growth. Zt/f2 or 5-FU treatment showed significant
effect on prevention of animal death, and their survival
rates significantly improved. In mice treated with Zt/f2
and 5-FU, four mice (50%) were still alive after a period
of 36 days. Thus, results in Figure 6 demonstrate that
Zt/f2 in combination with 5-FU prolongs the survival
rate of tumor-bearing mice.
Figure 4 Effect of Zt/f2 on RON expression by colon cancer cells. A) Down-regulation of RON/RON160 expression by Zt/f2. HT-29 cells (1 ×
10
6 cells/sample) were treated with Zt/f2 (10 μg/ml) or control mouse IgG at 37°C for 6 and 12 h. After treatment, cells were washed with
acidic buffer to eliminate surface-bound antibody (Guin et al., 2010) and then incubated with Zt/g4 (1 μg/sample) to detect RON/RON160
remaining on the cell surface by flow cytometric analysis. B) Preventive effect of filipin on Zt/f2-induced RON reduction. HT-29 cells were pre-
incubated with filipin (10 μg/ml) for 30 min and then treated at 37°C for 12 h with Zt/f2 or control mouse IgG (10 μg/ml). After washing with
acidic buffer, RON on cell surface was detected by Zt/g4 as previously described (Guin et al., 2010). C) Kinetic effect of Zt/f2 on RON/RON160
expression. HT-29 cells were treated with 10 μg/ml of Zt/f2 for various times. RON expression was determined by Western blot analysis. Normal
mouse IgG was used as the control. D) Preventive effect of lactacystin on Zt/f2-induced RON reduction. HT-29 cells were pre-incubated with 1 or
10 μg/ml of lactacystin for 30 min and then treated with 10 μg/ml of Zt/f2 at 37°C for 12 h. Levels of RON were determined by Western blot
analysis.
Yao et al. Molecular Cancer 2011, 10:82
http://www.molecular-cancer.com/content/10/1/82
Page 7 of 12Discussion
The major finding in this study is the therapeutic effec-
tiveness of mAb Zt/f2 on tumor growth mediated by
colon HT-29 and transformed 3T3 cells. RON as a drug
target for potential cancer therapy has been under inten-
sive investigation [25,26,32]. Various approaches includ-
ing specific siRNA, mAb, and small molecule kinase
inhibitors have been studied [25,26,32]. The data from
current studies indicate that blocking RON signal has
profound impact on tumor growth in animal models,
which could have clinical implication in the treatment of
human cancers. This conclusion is supported by data
from analysis of Zt/f2 biochemical properties and by eva-
luation of the effect of Zt/f2 on tumor growth in vivo. Zt/
f2 binds specifically to an epitope(s) located in MRS
c o d e db ye x o n1 1i nt h eR O Nb-chain extracellular
Figure 5 Inhibitory effect of Zt/f2 on 3H3-RON160 or HT-29 cell-mediated tumor growths. Induction of tumors in Balb/c mice by NIH3T3-
RON160 cells (A) or in athymic nude mice by HT-29 cells (B) was detailed in Materials and methods. Tumor bearing mice were randomized into
different groups (3 mice per group). Treatment of animals with Zt/f2, Zt/g4, or control mouse IgG at the defined dose and schedule as detailed
in Materials and Methods. Mice were euthanized at day 32 in both experiments. The therapeutic effect of Zt/f2 on tumor growth was obtained
by comparing tumor volumes among groups. Antibody injection is marked with arrows. Tumor growth index from control mice was set at 1.00
and used to compare the differences among groups.
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phosphorylation, it subsequently causes RON internaliza-
tion leading to diminished RON expression in cancer
cells. Such effect attenuates RON transduced signals
required for tumorigenic activities. As in vivo studies
have shown, administration of Zt/f2 as a single agent par-
tially inhibits tumor growth mediated by transformed
3T3 cells expressing RON160 in Balb/c mice and by
colon HT-29 cells expressing RON and RON160. More-
over, enhanced effects were achieved when Zt/f2 was
combined with chemotherapeutic agents such as 5-FU.
Thus, by targeting RON/RON160 overexpressed by can-
cer cells such as colon cancer cells, Zt/f2 is capable of
inhibiting tumor growth mediated by RON/RON160
signaling.
Zt/f2 specifically binds to an epitope in MRS coded by
exon 11 in the RON b-chain extracellular sequences.
This conclusion is derived by analyzing variants with
different deletions or truncations in RON extracellular
sequences and by competing with the synthetic peptide
with known sequences. Zt/f2 does not recognize RON-
sema, a truncated RON protein containing the entire
sema, PSI and a portion of the 1
st IPT unit [20]. How-
ever, Zt/f2 binds to RON160, which lacks the entire 1
st
IPT domain [33]. Since the RON extracellular sequences
contain more than 950 amino acids, analysis of Zt/f2
binding to RONsema and RON160 helps us investigate
potential regions in the remaining b-chain extracellular
sequences, which contain the 2
nd, and 3
rd IPT units and
the MRS. An important clue comes from the inability of
Zt/f2 to bind to RON165, which has a deletion of MRS
49 amino acids between the 3
rd IPT and the transmem-
brane segment. The 49 amino acids are exclusively
coded by exon 11 [22]. We also observed the failure of
Zt/f2 to bind to RON155. RON155 has two deletions,
one in 1
st IPT unit and the other in MRS. These results
suggest that MRS could be the potential region that Zt/
f2 binds. With the use of the synthetic peptide with 49
amino acids sequenced from exon 11, we showed that
pre-incubation of Zt/f2 with MRS peptide almost com-
pletely prevents Zt/f2 binding to RON or RON160
expressed on the cell surface. Thus, Zt/f2 binds to an
epitope that resides in MRS.
Zt/f2 binding to RON slightly increases receptor phos-
phorylation as shown Figure 3. Zt/f2 also moderately
synergizes with MSP in enhancement of RON and Erk1/2
phosphorylation. These results suggest that Zt/f2 engage-
ment with MRS is sufficient to cause conformational
changes for dimerization leading to RON phosphorylation
and activation of the downstream signaling cascade. How-
ever, Zt/f2 showed certain inhibitory effects on HT-29 cell
growth and migration. These suggest a disconnection
between Zt/f2-induced signaling events and biological out-
comes, which partially resemble anti-EGFR mAb cetuxi-
mab and matuzumab. Cetuximab and matuzumab induce
EGFR dimerization and phosphorylation, but fail to trigger
downstream signaling by AKT and Erk. By inhibiting the
EGF-induced activation of AKT and Erk, both mAbs inhi-
bit lung tumor growth in vivo [34,35]. Currently, the
mechanisms underlying disconnections between intracel-
lular signaling and cellular activity are unknown. A possi-
ble explanation is that Zt/f2-induced signaling is not
sustained long enough to initiate cell proliferation and
migration activities. Down-regulation by Zt/f2 of RON
expression as described in Figure 4 could be a major rea-
son. We also have observed that phosphorylation of RON
Figure 6 Enhanced activities of Zt/f2 and 5FU in inhibition of tumor growth. HT-29 cell-mediated tumor growth in athymic nude mice was
used as the model (O’Toole et al., 2006). Zt/f2 treatment began when tumor volumes reached about 9 mm
3 (around 8 days after cell
inoculation). A) Comparison of tumor weights from different groups of G-I. B) Survival rates in different groups of G-II. In both G-I and G-II,
statistical significance (p < 0.05) is indicated with a star.
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f2 treatment for 24 or 72 h (our unpublished data).
Regardless of these observations, it will be interesting in
the future to dissect cellular mechanisms responsible for
such disconnections.
The findings that Zt/f2 induces RON internalization and
degradation are interesting in terms of inhibitory effect in
vivo. Down-regulation of RTK expression is an anti-tumor
mechanism of therapeutic anti-RTK mAb such as trastu-
zumab specific to HER2 [36-38]. Results from current stu-
dies demonstrate that Zt/f2 treatment transiently induces
RON phosphorylation followed by down-regulation of
RON expression by HT-29 cancer cells. As shown in
Figure 4A, levels of RON on cell surface were progres-
sively diminished 6 h after Zt/f2 treatment. The mAb-
induced RTK down-regulation is a complicated process
involving receptor internalization followed by protein
degradation through intracellular mechanisms [37,39]. We
observed that the addition of filipin, an inhibitor of cellular
internalization process [31], prevents the effect of Zt/f2
on RON internalization. These results suggest that
Zt/f2-induced RON internalization is required for down-
regulation. Moreover, proteasomal inhibitor lactacystin
blocked Zt/f2-induced RON reduction. These data indi-
cate that the internalized RON proteins are degraded
through proteasomic mechanism. The diminished RON
expression could affect tumorigenic activities of colon can-
cer cells leading to impairment of their growth in vivo.
Inhibition of HT-29 cell-mediated tumor growth pro-
vides direct evidence indicating that Zt/f2 alone or in
combination with chemotherapeutic agent 5-FU has
potential therapeutic activities in vivo against tumor cells
expressing RON or RON160. Analysis of in vivo results
revealed several features of Zt/f2 as a therapeutic agent.
First, Zt/f2 used as a single agent is able to inhibit tumor
growth mediated by HT-29 and RON160 transformed
3T3 cells. Repeated administration of mAb is required to
achieve this effect. Second, Zt/f2 used in combination
with 5-FU shows the significant inhibition of tumor
growth. This suggests that enhanced activity is achieved
between Zt/f2-mediated inhibitory effect and chemoa-
gent-induced cytotoxicity. Third, the inhibitory effect of
Zt/f2 is seen in both Balb/c mice with normal immune
system and athymic nude mice lacking the T-cell-
mediated immunity. Fourth, Zt/f2 treatment alone shows
only partial inhibition of tumor growth. In both 3T3-
RON160 and HT-29-mediated tumors, only 55% inhibi-
tion was observed. Complete tumor remission was not
achieved. These results are in line with other anti-RON
mAbs such as IMC-41A40 [25]. IMC-41A40 shows
tumor inhibition at a range of about 50%. Studies using
small molecule kinase inhibitors specific to RON such as
compound I also have shown about 50% tumor inhibition
[26]. Clearly, additional measures are needed to achieve
the maximal therapeutic efficiency to completely block
tumor growth. Currently, the mechanisms underlying the
Zt/f2 action in vivo a r eu n k n o w n .M u l t i p l em e c h a n i s m s
including antibody-mediated immune reactions might be
involved in tumor growth inhibition. Nevertheless, data
from our current in vivo studies suggest that Zt/f2 has
potential for targeted cancer therapy. This work should
also provide the basis for future development of Zt/f2-
based cancer therapy.
Materials and methods
Cell Lines and Reagents
NIH3T3 cells expressing RON, RON165, RON160, or
RON110 were used as previously described [30]. Human
colon cancer HT-29 cells were from ATCC (Manassas,
VA). Mouse mAb Zt/g4 to the RONsema domain and
rabbit antibody to the RON C-terminal tail were used as
previously described [29]. Rabbit IgG cross-reacting with
RON from different species was from Santa Crutz Bio-
technology (Santa Crutz, CA). Mouse mAb to phos-
phor-tyrosine, Erk1/2, AKT, and other proteins were
from Cell Signaling (Danvers, MA). A peptide contain-
ing 49 amino acid coded by exon 11 of the RON gene
was synthesized as previously described [16]. Endocytic
inhibitor filipin, proteasomal inhibitor lactacystin, and
chemoagent 5-FU were from Fisher Scientific (Pitts-
burgh, PA).
Generation of hybridoma and purification of mAb
The classical hybridoma method was used to generate
mouse mAbs specific to human RON as previously
described [29]. NIH-3T3 cells expressing RON or
RON160 were used as immunogen to immunize Balb/c
mice. Spleen cells from immunized mice were fused
with S/p2 myeloma cells. Positive hybridoma lines were
established by limiting dilution. Several mAbs such as
Zt/f2 and Zt/#1 were purified from individual clones by
using protein G Sepharose affinity column.
Immunoprecipitation and Western blot analysis
These methods were performed using specific antibodies
as detailed previously [33]. RON and other proteins
were detected by Western blotting using specific antibo-
dies. The membrane also was reprobed with anti-b-actin
antibody to ensure the equal sample loading.
Labeling of mAb with FITC and Immunofluorescent cell
surface analysis
The labeling of Zt/f2 with FITC was performed using a
FITC labeling kit as previously described [29]. Fluores-
cent cell surface/cytoplasmic analysis was performed by
flow cytometry (FACScan, Becton Dickinson, Franklin
Lakes, NJ) as previously described [29]. Cells were treated
with specific mAb or control IgG for 45 min followed by
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nolaboratory, Bar Harbor, Maine).
Cell growth and migration assays
Proliferation of HT-29 cells was determined by counting
cell numbers three days after incubation with various
mAb as previously described [21]. Cell numbers from
individual samples in triplicate were determined by Cell-
ometer Auto-T4 counter (Nexcelon Inc., Lawrence, MA)
and expressed as a percentage of cell growth. HT-29 cell
migration was determined using a multi-well migration
chamber as previously described [28]. Migrated cells
were counted and expressed as a percentage of total cells.
In vivo tumor growth and treatment
Induction of tumor growth by 3T3-RON160 cells was
performed using Balb/c mice as previously described
[21]. HT-29 cell-mediated tumor growth was carried out
using athymic nude mice (Taconic, Cranbury, NJ)
according to a previously reported method [21]. Briefly,
3T3-RON160 (1 × 10
6 cells per mouse) or HT-29 (2 ×
10
6 cells per mouse) cells were subcutaneously injected
into the posterior flank of mice. Three days after inocula-
tion, mice were randomized into different groups. Ani-
mals were treated with i.p. injection every three days with
Zt/f2, Zt/g4, or control mouse IgG (three mice per
group) at a dose of 35 mg/kg. A total of six injections
were performed during the duration of the study.
Tumors were measured twice each week and tumor
volumes were calculated using the formula: 4(a x b),
where a was the larger and b was the smaller diameter.
For combined treatment, athymic nude mice inocu-
lated with HT-29 cells were used. Treatments began
when tumor volume had reached about 9 mm
3 (at about
day eight). Tumor bearing mice were randomly divided
into two groups: G-I and G-II. Mice within these two
groups were further randomized to one of the four treat-
ment groups (eight mice per group): PBS control; Zt/f2
treatment (35 mg/kg i.p, every four days for 20 days with
a total of five injections); 5-FU treatment (20 mg/kg i.p.
for seven continuous days); and Zt/f2 plus 5-FU treat-
ment (combination of Zt/f2 and 5-FU). Mice in G-I were
euthanized on day 25 and tumors were weighted and
compared among the four groups. Mice in G-II were
observed until no survival existed in the PBS group and
survival rates were compared among the groups. Differ-
e n c e si nm e a nt u m o rv o l u m ea n di nm e a ns u r v i v a lr a t e
were evaluated by Student’s t-test. The p value of com-
parison (< 0.05) was considered as significant.
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